MicroRNA‑153 may act as a potential biomarker and prognostic indicator of patients with gastric cancer

• Published in: Oncology letters Vol. 26; no. 1; p. 278
• Main Authors: Li, Tian, Guo, Dong, Xu, Xiaoyan, Liu, Peng, Wang, Ping, Zhu, Yongcun, Lin, Lin, Qu, Yemin, Liu, Feng, Chu, Yanliu, Gao, Xiaozhong
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.07.2023; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Apoptosis; Bioinformatics; Biomarkers; Biotechnology; Biotechnology industry; Breast cancer; Cancer; Cancer patients; Colorectal cancer; Development and progression; Gastric cancer; Genomes; Health aspects; Medical prognosis; MicroRNA; MicroRNAs; Oncology; Oncology, Experimental; Photographic industry; Scientific equipment and supplies industry; Stomach cancer; Tumors; United States; Japan; China; Beijing China; gastric cancer; proliferation; microRNA-153; migration; apoptosis; biomarker; prognosis
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2023.13864

MicroRNA (miR/miRNA)-153, as a novel tumor-related miRNA, has been found to be aberrantly expressed in different types of cancer; however, to the best of our knowledge, the role of miR-153 in gastric cancer (GC) remains unclear. The present study demonstrated that miR-153 expression was markedly decreased in GC, including GC cell lines and culture medium, GC tissues, and serum samples, based on reverse transcription-quantitative PCR, and this was further confirmed by fluorescence hybridization. Transfection with miR-153 mimics inhibited proliferation and migration, and promoted apoptosis in GC cells. The serum expression levels of miR-153 were decreased in 59 patients with GC compared with those of 9 healthy controls, and more decreased in advanced GC compared with early-stage GC, suggesting that miR-153 was associated with tumor progression. Furthermore, serum miR-153 was expressed at significantly lower levels in patients with GC with larger tumor size (≥4 cm; P=0.013), poor differentiation and signet histology (P=0.013), lymph node metastasis (P=0.025) and advanced tumor stage (TNM stage III and IV; P=0.048) compared with patients with a smaller tumor size (<4 cm), well and moderate differentiation, no lymph node metastasis, and TNM stage I and II, respectively. In conclusion, the present study revealed that low miR-153 expression was associated with poor prognosis in GC and miR-153 may potentially act as a tumor biomarker and therapeutic target in GC.